CARG-2020
Ovarian Cancer
Pre-clinicalActive
Key Facts
About CaroGen
CaroGen is a private, pre-clinical-stage biotech developing immunotherapies using its innovative AVIDIO platform, an RNA-based artificial virus technology capable of delivering multiple transgenes to elicit broad immune responses. Its pipeline features two late-stage pre-clinical candidates: CARG-2020 for ovarian cancer and CARG-201 for chronic hepatitis B (CHB). The company is backed by significant non-dilutive funding from the NIH and DoD, exceeding $16 million for its HBV program, and holds a broad patent portfolio covering composition of matter and methods of use.
View full company profileTherapeutic Areas
Other Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| EXO‑Ovarian Cancer Test | INOVIQ | Phase 2/3 |
| CAR‑iNK‑OvCa | Cartherics | Preclinical |
| MagSense™ FR Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Yondelis (trabectedin) | PharmaMar | Approved |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| NP-G2-044 + Chemotherapy Agents | Novita Pharmaceuticals | Phase 2a |
| Ivospemin (SBP-101) | Panbela Therapeutics | Phase 2 |
| Ovarian Cancer Early Detection Assay | GenEndeavor | Pre-clinical |
| INVAC-1 | Invectys | Phase 2 |
| Folate Receptor-Targeted PCC | Indi Molecular | Preclinical |
| Immunomodulator Platform | OmniCyte | Pre-clinical |
| Platform Candidate | FLAG Therapeutics | Preclinical |